新光药业(300519) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥93,250,095.71, a decrease of 7.26% compared to ¥100,545,259.30 in the same period last year[5] - Net profit attributable to shareholders increased by 7.50% to ¥24,541,781.11 from ¥22,830,341.36 year-on-year[5] - Basic and diluted earnings per share both increased by 7.14% to ¥0.15 from ¥0.14 in the same period last year[5] - Total operating revenue for the current period is CNY 93,250,095.71, a decrease of 7.8% from CNY 100,545,259.30 in the previous period[20] - Net profit for the current period is CNY 24,541,781.11, up 7.5% from CNY 22,830,341.36 in the previous period[21] - Earnings per share increased to CNY 0.15 from CNY 0.14, representing a growth of 7.1%[22] Cash Flow - The net cash flow from operating activities rose by 7.60% to ¥41,825,265.23 compared to ¥38,871,503.24 in the previous year[5] - Cash flow from operating activities was CNY 99,159,239.63, compared to CNY 104,202,561.78 in the previous period[24] - Net cash flow from operating activities amounted to $41,825,265.23, an increase of 7.5% compared to $38,871,503.24 in the previous period[25] - Cash received from other operating activities increased by 268.31% to ¥8,640,620.62 compared to ¥2,346,013.10 in the same period last year[10] - Total cash outflow from operating activities was $65,974,595.02, a decrease of 2.5% from $67,677,071.64 year-over-year[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥923,934,006.86, reflecting a 1.56% increase from ¥909,781,335.37 at the end of the previous year[5] - Total current assets amount to 792,156,050.08 RMB, an increase from 774,713,254.45 RMB at the beginning of the period[17] - Total liabilities decreased to CNY 68,927,168.10 from CNY 79,249,505.77, a reduction of 13.0%[18] - Total equity increased to CNY 855,006,838.76 from CNY 830,531,829.60, reflecting a growth of 2.9%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,470[13] - The largest shareholder, Wang Yuejun, holds 38.25% of shares, totaling 61,200,000 shares[13] - The company has a total of 45,900,000 restricted shares held by Wang Yuejun, with no shares released during the period[15] Expenses - The company's financial expenses saw a significant increase of 337.67%, primarily due to increased bank interest income during the reporting period[9] - Total operating costs decreased to CNY 66,920,864.51 from CNY 76,153,559.49, reflecting a reduction of 12.5%[20] - Research and development expenses rose to CNY 4,277,457.45 from CNY 3,945,710.79, an increase of 8.4%[21] - Payments to employees increased to $11,686,571.92, up from $10,575,614.30, reflecting a rise of 10.5%[25] - Payments for taxes amounted to $13,434,788.30, slightly up from $13,214,297.95, indicating a marginal increase of 1.7%[25] Other Financial Metrics - The cash received from other operating activities was $8,640,620.62, compared to $2,346,013.10 in the prior period, indicating a significant increase[25] - Other comprehensive income after tax decreased to CNY -66,771.95 from CNY -407,242.18, indicating a reduction in losses[22] - Financial expenses showed a significant improvement, with a net income of CNY -8,267,487.56 compared to CNY -1,888,989.28 in the previous period[21] - Total cash inflow from investment activities was $95,881,420.44, down 9.5% from $106,261,564.38 year-over-year[25] - Cash outflow from investment activities totaled $80,839,886.25, a decrease of 13.3% compared to $93,235,040.60 in the prior period[25]